BioCentury

8:00 AM GMT, Mar 8, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 3/5 cls
Actelion Ltd. (SIX:ATLN) Jefferies Peter Welford Price target Buy -13% CHF47.80
Welford lowered his target to CHF73 from CHF90 after Tracleer bosentan missed the primary endpoint in the Phase III BUILD-3 trial to treat idiopathic pulmonary fibrosis. Welford still rates the stock a buy, saying the company's pipeline is underappreciated. He expects Phase III data for clazosentan to prevent aneurysmal subarachnoid hemorrhage (aSAH) next half and Phase II data for selexipag to treat pulmonary arterial hypertension (PAH) in May. Clazosentan is an endothelin receptor antagonist and selexipag is a long-acting prostacyclin (IP) receptor (PGI2) agonist (see

Read the full 1231 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.